Ketamine and other NMDA antagonists: Early clinical trials and possible mechanisms in depression

The APA Council of Research Task Force on Novel Biomarkers and Treatments

Research output: Contribution to journalArticle

225 Citations (Scopus)

Abstract

Objective: Theauthorsconductedasystematic reviewandmetaanalysis of ketamine and other N-methyl-D-aspartate (NMDA) receptor antagonists in the treatment of major depression. Method: Searches of MEDLINE, PsycINFO, and other databases were conducted for placebo-controlled, double-blind, randomizedclinical trials ofNMDAantagonists inthetreatment of depression. Primary outcomes were rates of treatment response and transient remission of symptoms. Secondary outcomes included change in depression symptom severity and the frequency and severity of dissociative and psychotomimetic effects. Results for each NMDA antagonist were combined inmeta-analyses, reporting odds ratios for dichotomous outcomes and standardized mean differences for continuous outcomes. Results: Ketamine (seven trials encompassing 147 ketaminetreated participants) produced a rapid, yet transient, antidepressant effect, with odds ratios for response and transient remission of symptoms at 24 hours equaling 9.87 (4.37?22.29) and 14.47 (2.67?78.49), respectively, accompanied by brief psychotomimetic and dissociative effects. Ketamine augmentation of ECT (five trials encompassing 89 ketaminetreatedparticipants) significantlyreduceddepressive symptoms following aninitial treatment (Hedges?g50.933) but not at the conclusion of theECTcourse. OtherNMDAantagonists failed to consistently demonstrate efficacy; however, two partial agonists at the NMDA coagonist site, D-cycloserine and rapastinel, significantly reduced depressive symptoms without psychotomimetic or dissociative effects. Conclusions: The antidepressant efficacy of ketamine, and perhaps D-cycloserine and rapastinel, holds promise for future glutamate-modulating strategies; however, the ineffectiveness of other NMDA antagonists suggests that any forthcoming advances will depend on improving our understanding of ketamine?s mechanism of action. The fleeting nature of ketamine?s therapeutic benefit, coupled with its potential for abuse and neurotoxicity, suggest that its use in the clinical setting warrants caution.

Original languageEnglish (US)
Pages (from-to)950-966
Number of pages17
JournalAmerican Journal of Psychiatry
Volume172
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Ketamine
N-Methylaspartate
Clinical Trials
Depression
Cycloserine
Antidepressive Agents
Odds Ratio
Therapeutics
N-Methyl-D-Aspartate Receptors
MEDLINE
Glutamic Acid
Placebos
Databases

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Ketamine and other NMDA antagonists : Early clinical trials and possible mechanisms in depression. / The APA Council of Research Task Force on Novel Biomarkers and Treatments.

In: American Journal of Psychiatry, Vol. 172, No. 10, 01.10.2015, p. 950-966.

Research output: Contribution to journalArticle

The APA Council of Research Task Force on Novel Biomarkers and Treatments 2015, 'Ketamine and other NMDA antagonists: Early clinical trials and possible mechanisms in depression', American Journal of Psychiatry, vol. 172, no. 10, pp. 950-966. https://doi.org/10.1176/appi.ajp.2015.15040465
The APA Council of Research Task Force on Novel Biomarkers and Treatments. / Ketamine and other NMDA antagonists : Early clinical trials and possible mechanisms in depression. In: American Journal of Psychiatry. 2015 ; Vol. 172, No. 10. pp. 950-966.
@article{8e17ab1864914db89c9c94e70ec04467,
title = "Ketamine and other NMDA antagonists: Early clinical trials and possible mechanisms in depression",
abstract = "Objective: Theauthorsconductedasystematic reviewandmetaanalysis of ketamine and other N-methyl-D-aspartate (NMDA) receptor antagonists in the treatment of major depression. Method: Searches of MEDLINE, PsycINFO, and other databases were conducted for placebo-controlled, double-blind, randomizedclinical trials ofNMDAantagonists inthetreatment of depression. Primary outcomes were rates of treatment response and transient remission of symptoms. Secondary outcomes included change in depression symptom severity and the frequency and severity of dissociative and psychotomimetic effects. Results for each NMDA antagonist were combined inmeta-analyses, reporting odds ratios for dichotomous outcomes and standardized mean differences for continuous outcomes. Results: Ketamine (seven trials encompassing 147 ketaminetreated participants) produced a rapid, yet transient, antidepressant effect, with odds ratios for response and transient remission of symptoms at 24 hours equaling 9.87 (4.37?22.29) and 14.47 (2.67?78.49), respectively, accompanied by brief psychotomimetic and dissociative effects. Ketamine augmentation of ECT (five trials encompassing 89 ketaminetreatedparticipants) significantlyreduceddepressive symptoms following aninitial treatment (Hedges?g50.933) but not at the conclusion of theECTcourse. OtherNMDAantagonists failed to consistently demonstrate efficacy; however, two partial agonists at the NMDA coagonist site, D-cycloserine and rapastinel, significantly reduced depressive symptoms without psychotomimetic or dissociative effects. Conclusions: The antidepressant efficacy of ketamine, and perhaps D-cycloserine and rapastinel, holds promise for future glutamate-modulating strategies; however, the ineffectiveness of other NMDA antagonists suggests that any forthcoming advances will depend on improving our understanding of ketamine?s mechanism of action. The fleeting nature of ketamine?s therapeutic benefit, coupled with its potential for abuse and neurotoxicity, suggest that its use in the clinical setting warrants caution.",
author = "{The APA Council of Research Task Force on Novel Biomarkers and Treatments} and Newport, {Donald J} and Carpenter, {Linda L.} and McDonald, {William M.} and Potash, {James B.} and Mauricio Tohen and Charles Nemeroff",
year = "2015",
month = "10",
day = "1",
doi = "10.1176/appi.ajp.2015.15040465",
language = "English (US)",
volume = "172",
pages = "950--966",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "10",

}

TY - JOUR

T1 - Ketamine and other NMDA antagonists

T2 - Early clinical trials and possible mechanisms in depression

AU - The APA Council of Research Task Force on Novel Biomarkers and Treatments

AU - Newport, Donald J

AU - Carpenter, Linda L.

AU - McDonald, William M.

AU - Potash, James B.

AU - Tohen, Mauricio

AU - Nemeroff, Charles

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Objective: Theauthorsconductedasystematic reviewandmetaanalysis of ketamine and other N-methyl-D-aspartate (NMDA) receptor antagonists in the treatment of major depression. Method: Searches of MEDLINE, PsycINFO, and other databases were conducted for placebo-controlled, double-blind, randomizedclinical trials ofNMDAantagonists inthetreatment of depression. Primary outcomes were rates of treatment response and transient remission of symptoms. Secondary outcomes included change in depression symptom severity and the frequency and severity of dissociative and psychotomimetic effects. Results for each NMDA antagonist were combined inmeta-analyses, reporting odds ratios for dichotomous outcomes and standardized mean differences for continuous outcomes. Results: Ketamine (seven trials encompassing 147 ketaminetreated participants) produced a rapid, yet transient, antidepressant effect, with odds ratios for response and transient remission of symptoms at 24 hours equaling 9.87 (4.37?22.29) and 14.47 (2.67?78.49), respectively, accompanied by brief psychotomimetic and dissociative effects. Ketamine augmentation of ECT (five trials encompassing 89 ketaminetreatedparticipants) significantlyreduceddepressive symptoms following aninitial treatment (Hedges?g50.933) but not at the conclusion of theECTcourse. OtherNMDAantagonists failed to consistently demonstrate efficacy; however, two partial agonists at the NMDA coagonist site, D-cycloserine and rapastinel, significantly reduced depressive symptoms without psychotomimetic or dissociative effects. Conclusions: The antidepressant efficacy of ketamine, and perhaps D-cycloserine and rapastinel, holds promise for future glutamate-modulating strategies; however, the ineffectiveness of other NMDA antagonists suggests that any forthcoming advances will depend on improving our understanding of ketamine?s mechanism of action. The fleeting nature of ketamine?s therapeutic benefit, coupled with its potential for abuse and neurotoxicity, suggest that its use in the clinical setting warrants caution.

AB - Objective: Theauthorsconductedasystematic reviewandmetaanalysis of ketamine and other N-methyl-D-aspartate (NMDA) receptor antagonists in the treatment of major depression. Method: Searches of MEDLINE, PsycINFO, and other databases were conducted for placebo-controlled, double-blind, randomizedclinical trials ofNMDAantagonists inthetreatment of depression. Primary outcomes were rates of treatment response and transient remission of symptoms. Secondary outcomes included change in depression symptom severity and the frequency and severity of dissociative and psychotomimetic effects. Results for each NMDA antagonist were combined inmeta-analyses, reporting odds ratios for dichotomous outcomes and standardized mean differences for continuous outcomes. Results: Ketamine (seven trials encompassing 147 ketaminetreated participants) produced a rapid, yet transient, antidepressant effect, with odds ratios for response and transient remission of symptoms at 24 hours equaling 9.87 (4.37?22.29) and 14.47 (2.67?78.49), respectively, accompanied by brief psychotomimetic and dissociative effects. Ketamine augmentation of ECT (five trials encompassing 89 ketaminetreatedparticipants) significantlyreduceddepressive symptoms following aninitial treatment (Hedges?g50.933) but not at the conclusion of theECTcourse. OtherNMDAantagonists failed to consistently demonstrate efficacy; however, two partial agonists at the NMDA coagonist site, D-cycloserine and rapastinel, significantly reduced depressive symptoms without psychotomimetic or dissociative effects. Conclusions: The antidepressant efficacy of ketamine, and perhaps D-cycloserine and rapastinel, holds promise for future glutamate-modulating strategies; however, the ineffectiveness of other NMDA antagonists suggests that any forthcoming advances will depend on improving our understanding of ketamine?s mechanism of action. The fleeting nature of ketamine?s therapeutic benefit, coupled with its potential for abuse and neurotoxicity, suggest that its use in the clinical setting warrants caution.

UR - http://www.scopus.com/inward/record.url?scp=84942851296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942851296&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2015.15040465

DO - 10.1176/appi.ajp.2015.15040465

M3 - Article

C2 - 26423481

AN - SCOPUS:84942851296

VL - 172

SP - 950

EP - 966

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 10

ER -